Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-Risk Primary Gastrointestinal Stromal Tumor (GIST)

Closed

Phase

Published

Abbreviated Title

High Risk Primary GIST

Activated

10/01/2002

Closed

09/30/2003

Participants

CTSU

Research committees

Sarcoma

Treatment

STI-571/Imatinib Surgery

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information.

Publication Information Expand/Collapse

2013

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor ACOSOG Z9000 (Alliance) intergroup phase 2 trial

R Dematteo;K Ballman;C Antonescu;C Corless;V Kolesnikova;M Von Mehren;M McCarter;J Norton;R Maki;P Pisters;G Demetri;M Brennan;K Owzar Annals of Surgery 258(3):422-429;

PMid: PMID23860199 | PMC number: pending

2012

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence

M McCarter;C Antonescu;KV Ballman;R Maki;P Pisters;G Demetri;CD Blanke;M von Mehren;MF Brennan;L McCall;D Ota;R DeMatteo Journal of the American College of Surgeons 215(1):53-59

PMid: PMID22726733 | PMC number: PMC3383609

2005

Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup phase II trial ACOSOG Z9000

RP Dematteo;CR Antonescu;V Chadaram;YN You;L McCall;R Maki;A Murgo;G Demetri;P Pisters;MF Brennan Proc of the ASCO, JCO 23(16S):818s (#9009)